| Autor: |
Yasuo Suzuki, Naonobu Sugiyama, Yuri Fukuma, Noriko Sugiyama, Takeshi Kokubo |
| Předmět: |
|
| Zdroj: |
Modern Rheumatology; January 2020, Vol. 30 Issue 1, pvii-xviii, 12p |
| Abstrakt: |
Objectives: To confirm the safety and effectiveness of high-dose (>8mg/week) methotrexate (MTX) for the treatment of rheumatoid arthritis in Japan. Methods: A postmarketing surveillance program enrolled Japanese patients with rheumatoid arthritis starting on high-dose MTX followed up for either 24- or 52-weeks. Analyses for safety, risk factors affecting safety, and effectiveness were conducted. Results: The safety/effectiveness analysis sets included 2838/2779 and 335/326 patients in the 24-weeks and 52-weeks follow-up groups, respectively. Incidence rates of adverse drug reactions (ADRs) and serious ADRs were 21.42% and 1.66% in the 24-weeks, and 35.52% and 2.69% in the 52-weeks groups, respectively. The Disease Activity Score in 28 Joints (DAS28) was significantly decreased as early as four weeks from the start of high-dose MTX; after 24-weeks (4.09-3.21) and 52-weeks of treatment (3.91-2.80; both p<.001). In a majority of patients at baseline who had high-to-moderate disease activity, the remission rate (defined as DAS<2.6) increased three-fold from 10.6% (baseline) to 33.0% (24-weeks) compared to patients with low disease activity whose remission rate increased two-fold from 24.0% (baseline) to 53.6% (24-weeks). Conclusions: High-dose MTX was well tolerated in Japanese patients, resulted in improved disease control, and can be considered a step forward in achieving treat-to-target goals. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
